Industry News
Biotechnology Industry News
For the second time, Astellas is…
For the second time, Astellas is walking away from Taysha Gene Therapies, this time choosing not to license the biotech’s adeno-associated-virus-based therapy designed to treat a rare neurodevelopmental condition.
Less than two years after laying…
Less than two years after laying out plans to divest its China operations and become a U.S.-focused biotech, I-Mab Biopharma is re-staking its claim in the Asia-Pacific region.
Hansoh has announced a deal with…
Hansoh has announced a deal with Roche worth up to $1.45 billion biobucks to grant the Swiss drugmaker a global license to develop, manufacture and sell its experimental ADC. At the same time, Rani has
The FDA made waves in early…
The FDA made waves in early September when it announced a plan to publicly release complete response letters, or CRLs, at the same time they are issued to sponsoring companies. What risks and opportunities does
Bristol Myers Squibb touted a 55%…
Bristol Myers Squibb touted a 55% overall response rate from one cohort of an early-stage study of its EGFRxHER3 antibody-drug conjugate.
The FDA’s cancellation of a…
The FDA’s cancellation of a meeting to discuss the next steps in a R&D program has prompted Kezar Life Sciences to prepare to lay off staff and explore strategic alternatives.
The FDA has handed out the first…
The FDA has handed out the first nine national priority vouchers, positioning companies including Merck KGaA, Regeneron and Sanofi to complete the approval process in one to two months.
Gilead’s Kite Pharma is doubling…
Gilead’s Kite Pharma is doubling down on in vivo CAR-T, this time inking a deal worth up to $1.64 billion biobucks with China biotech Pregene Biopharma.
The trials demonstrated the…
The trials demonstrated the benefits of Praxis' ulixacaltamide in essential tremor after a previously grim outlook at an interim analysis of one of the studies earlier this year.
French antibody specialist…
French antibody specialist Adcytherix has added a €105 million ($122 million) series A to its coffers, which the Marseille-based biotech will use to push its lead antibody-drug conjugate into clinical trials.
Dianthus Therapeutics is offering…
Dianthus Therapeutics is offering Nanjing Leads Biolabs up to $1 billion biobucks for licensing rights to a bifunctional fusion protein designed to treat certain autoimmune disorders.
University of Michigan spinout…
University of Michigan spinout Evoq Therapeutics has struck its third major partnership with a biopharma powerhouse, signing on with Sanofi in a deal worth up to $500 million. The agreement comes after Evoq entered deals
AstraZeneca has returned to its…
AstraZeneca has returned to its longtime AI partner Immunai with a new deal worth up to $85 million to advance a target for a new inflammatory bowel disease therapy.
As geopolitical tensions rise,…
As geopolitical tensions rise, Nkarta CEO Paul Hastings is urging the U.S. government not to impose restrictions on Chinese scientific collaboration and refocus on what matters most: the patient.
Boehringer Ingelheim will pay…
Boehringer Ingelheim will pay AimedBio up to $991 million to license and develop one of the South Korean biotech’s antibody-drug conjugates across a “broad range of cancers." The ADC asset girding the deal targets a
Eli Lilly has guided its oral…
Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek approval in
After Omeros decided to hit pause…
After Omeros decided to hit pause on developing its MASP-3 inhibitor zaltenibart, Novo Nordisk has spied an opportunity to scoop up the rare disease drug.
Aicuris has reported the success…
Aicuris has reported the success of a phase 3 trial, which has demonstrated the superiority of oral antiviral pritelivir compared to standard-of-care treatments in healing lesions of immunocompromised patients with refractory HSV infections. The study
The latest strand in Pelage…
The latest strand in Pelage Pharmaceuticals' growing funds comes from a $120 million series B fundraising round the biotech plans to apply to its regenerative hair loss treatment.
BioCryst Pharmaceuticals has…
BioCryst Pharmaceuticals has struck a $700 million deal to buy Astria Therapeutics. The deal will give the rare disease specialist control of a phase 3 challenger to Takeda’s hereditary angioedema therapy Takhzyro.